ALNOV Fundamental Analysis - NOVACYT

Fundamental Rating

ALNOV gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 86 industry peers in the Biotechnology industry. The financial health of ALNOV is average, but there are quite some concerns on its profitability. ALNOV is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALNOV had negative earnings in the past year.
ALNOV had a negative operating cash flow in the past year.
In the past 5 years ALNOV reported 4 times negative net income.
In multiple years ALNOV reported negative operating cash flow during the last 5 years.

1.2 Ratios

With a Return On Assets value of -48.32%, ALNOV is not doing good in the industry: 60.24% of the companies in the same industry are doing better.
ALNOV has a Return On Equity (-74.44%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-48.32%
ROE	-74.44%
ROIC	N/A

ROA(3y)-32.84%

ROA(5y)-9.46%

ROE(3y)-47.33%

ROE(5y)-12.19%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 63.35%, ALNOV perfoms like the industry average, outperforming 57.83% of the companies in the same industry.
In the last couple of years the Gross Margin of ALNOV has grown nicely.
The Profit Margin and Operating Margin are not available for ALNOV so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	63.35%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y75.01%

GM growth 5Y20.62%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALNOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALNOV has about the same amount of shares outstanding.
The number of shares outstanding for ALNOV has been increased compared to 5 years ago.
The debt/assets ratio for ALNOV is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of 0.45, we must say that ALNOV is in the distress zone and has some risk of bankruptcy.
ALNOV has a Altman-Z score of 0.45. This is comparable to the rest of the industry: ALNOV outperforms 55.42% of its industry peers.
ALNOV has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ALNOV (0.24) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.24
Debt/FCF	N/A
Altman-Z	0.45

ROIC/WACCN/A

WACC6.67%

2.3 Liquidity

ALNOV has a Current Ratio of 5.03. This indicates that ALNOV is financially healthy and has no problem in meeting its short term obligations.
ALNOV's Current ratio of 5.03 is amongst the best of the industry. ALNOV outperforms 80.72% of its industry peers.
ALNOV has a Quick Ratio of 4.59. This indicates that ALNOV is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.59, ALNOV belongs to the top of the industry, outperforming 80.72% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	5.03
Quick Ratio	4.59

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 17.85% over the past year.
The Revenue has grown by 8.50% in the past year. This is quite good.
Measured over the past years, ALNOV shows a quite strong growth in Revenue. The Revenue has been growing by 11.35% on average per year.

EPS 1Y (TTM)17.85%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%61.73%

Revenue 1Y (TTM)8.5%

Revenue growth 3Y-40.37%

Revenue growth 5Y11.35%

Sales Q2Q%-5.12%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALNOV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALNOV does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

NOVACYT

EPA:ALNOV (1/16/2026, 7:00:00 PM)

0.3935

-0.01 (-2.72%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)09-30 2025-09-30

Earnings (Next)N/A N/A

Inst Owners0.05%

Inst Owner ChangeN/A

Ins Owners0.06%

Ins Owner ChangeN/A

Market Cap27.79M

Revenue(TTM)19.10M

Net Income(TTM)-30.40M

Analysts37.14

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	1.26
P/FCF	N/A
P/OCF	N/A
P/B	0.59
P/tB	1.11
EV/EBITDA	N/A

EPS(TTM)-0.5

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.13

FCFYN/A

OCF(TTM)-0.1

OCFYN/A

SpS0.31

BVpS0.67

TBVpS0.35

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-48.32%
ROE	-74.44%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	63.35%
FCFM	N/A

ROA(3y)-32.84%

ROA(5y)-9.46%

ROE(3y)-47.33%

ROE(5y)-12.19%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y75.01%

GM growth 5Y20.62%

F-Score4

Asset Turnover0.3

Health

		Industry Rank	Sector Rank
Debt/Equity	0.24
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	8.2%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	5.03
Quick Ratio	4.59
Altman-Z	0.45

F-Score4

WACC6.67%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)5.93%

Cap/Sales(5y)4.53%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)17.85%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%61.73%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)8.5%

Revenue growth 3Y-40.37%

Revenue growth 5Y11.35%

Sales Q2Q%-5.12%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y32.92%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y56.9%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y65.03%

OCF growth 3YN/A

OCF growth 5YN/A

NOVACYT / ALNOV.PA FAQ

What is the ChartMill fundamental rating of NOVACYT (ALNOV.PA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALNOV.PA.

Can you provide the valuation status for NOVACYT?

ChartMill assigns a valuation rating of 0 / 10 to NOVACYT (ALNOV.PA). This can be considered as Overvalued.

Can you provide the profitability details for NOVACYT?

NOVACYT (ALNOV.PA) has a profitability rating of 1 / 10.

What is the financial health of NOVACYT (ALNOV.PA) stock?

The financial health rating of NOVACYT (ALNOV.PA) is 4 / 10.

NOVACYT (ALNOV.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

NOVACYT / ALNOV.PA FAQ

What is the ChartMill fundamental rating of NOVACYT (ALNOV.PA) stock?

Can you provide the valuation status for NOVACYT?

Can you provide the profitability details for NOVACYT?

What is the financial health of NOVACYT (ALNOV.PA) stock?